バイオ研究者・大学院生のための簡単な英語文例集

その８　ＮＩＨの遺伝子治療に関するガイドライン
ヒトの遺伝子治療の臨床研究の際の副作用の報告義務に関するプロポーザルです。その９のアメリカ遺伝子治療学会の見解と併せて読んでみてください。また、これに関連したニュースが雑誌 (FDA to release data on gene therapy trials. in Science 291: 572-573,2001) に載っておりますので、こちらも併せご覧ください。また、バイオ研究者のための英語のその２３でも解説します。

DEPARTMENT OF HEALTH AND HUMAN SERVICES 

National Institutes of Health Office of Biotechnology Activities; Recombinant DNA Research: Proposed Actions Under the NIH Guidelines AGENCY: National Institutes of Health (NIH), PHS, DHHS. 

ACTION: Notice of proposed actions under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). 

SUMMARY: The NIH is proposing changes to the NIH Guidelines to enhance its oversight of human gene transfer research by making modifications to the reporting and analysis of serious adverse events in human gene transfer research studies. The purpose of this Notice is to inform the public about the proposed changes and to seek public comment on them. The proposed changes involve four main issues: (1) The scope and timing of serious adverse event reporting; (2) public access to information about serious adverse events; (3) protection of individually identifiable patient information as it relates to serious adverse event reporting; and (4) a new mechanism for the review and assessment of data on serious adverse events and other relevant safety information.

The NIH currently requires all serious adverse events to be reported immediately whether or not they are expected or considered to be associated with the gene transfer product. The first proposed change would require expedited reporting for those serious adverse events that are unexpected and considered possibly associated with the use of the gene transfer product. The proposed change also provides timeframes for expedited reporting and definitions of serious, associated, and unexpected adverse events. Under this proposal, other reportable serious adverse events would be included in annual reports.

The second proposed change would clarify that serious adverse event reports submitted to the NIH may not be classified as confidential information and that trade secret or other commercial confidential information should not be included in serious adverse event reports.

The third proposed change adds specific language to the NIH Guidelines to prohibit the submission of individually-identifiable patient information in serious adverse event reports.

The fourth and final change is the establishment of a working group of the NIH Recombinant DNA Advisory Committee (RAC), to be known as the NIH Gene Transfer Safety Assessment Board, that will be responsible for the review and analysis of serious adverse event reports and other relevant safety information in gene transfer research studies. The working group will report safety information to the RAC and information will, thereby, be disseminated to the scientific and patient communities and the public.

バイオ研究者のための英語　目次へ

＊＊＊＊＊＊

最新の近況報告のページ